University of Washington

Novartis Vaccines & Diagnostics, Gmbh

Alza Corporation

British Technology Group USA

Ultra Diagnostics Corporation

Niels H Andersen

Jason Bowman

Keith Bruce Pfister

Allan S Wagman

Toni Beth Kline

Simon C Ng

Eric Harwood

Asha Yabannavar

Alice L Erwin

Ribhi Shawar

Khisimuzi E Mdluli

Deborah C Schindele

George E Renzoni

Thomas H Stanton

Ned M Weinshenker

Karen L Fearon

Barry V Pepich

James A Clagett

Kent E Opheim

Antibacterial compounds of formula I are provided:  As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.

Antibacterial agents

Fluorescent and/or chromogenic reagents in which a phthalocyanine derivative is monomerically conjugated with an antigen, antibody, oligonucleotide, or nucleic acid. Methods are presented in in which greater than 90% of the phthalocyanine dyes are monomeric when conjugated. This greatly enhances their performance as detectable markers in immunoassays, nucleic acid probe assays, immunoblotting, hybridization assays, microscopy, imaging, flow cytometry, DNA sequencing, and photodynamic therapy. For use as fluorophores, the free base phthalocyanine may or may not be metallated. Metals for fluorescent phthalocyanine include aluminum, silicon, phosphorus, gallium, germanium, cadmium, scandium, magnesium, tin, and zinc. For use as chromogens, the phthalocyanine may or may not be metallated. For use in aqueous solution, the phthalocyanine macrocycle should be derivatized with water-solubilizing substituents such as sulfonic acid, phosphate, phosphonate, hydroxy, phenoxy, amino, ammonium, or pyridinium groups. To promote disaggregation, metallation with an atom of +3 valence or higher is recommended, so that the monomer will take on an axial ligand in aqueous solution. For use in enzymatic immunoassays and enzymatically enhanced nucleic acid probe assays, the monomeric phthalocyanine derivative is conjugated via an enzyme-cleavable linkage with the antigen, antibody, oligonucleotide, or nucleic acid. Reversibly quenched embodiments are also provided in which a cleavable linkage joins a fluorescent phthalocyanine monomer with another phthalocyanine, a heavy metal, or a paramagnetic species.

Monomeric phthalocyanine reagents

An immunoassay device including one or more reaction chambers, each adapted to receive and retain a volume of test fluid in fluid communication with nonoverlapping first, second, and third reagent-bearing surfaces. To the first surface is reversibly bound an analyte conjugate: analyte component conjugated to one or more components, termed ligand/marker, that serve ligand and marker functions as described herein. Analyte binding partner is immobilized on the second surface, and ligand/marker binding partner is immobilized on the third surface. The reaction chamber is preferably configured to receive and direct the test fluid sequentially past the first second, and third reagent surfaces. In use, analyte conjugate solubilized from the first surface completes with any analyte in the test fluid for analyte binding partner sites on the second surface. Excess analyte conjugate becomes sequestered on the third surface, where the marker activity is read to indicate analyte presence and concentration in the test fluid. A test kit includes the immunoassay device in combination with comparative test results.

Competitive immunoassay method, device and test kit

Novel alkyl diethers of prostaglandins of the formula; ##STR1## wherein R.sub.1 is hydrogen or lower alkyl; R.sub.2 and R.sub.6 are hydrogen when Y is a single bond and R.sub.2 and R.sub.6 are absent when Y is a double bond; R.sub.3 is keto, ##STR2## R.sub.4 is hydrogen or ##STR3## R'.sub.9 is hydrogen or lower alkyl; R'.sub.10 is lower alkyl; R'.sub.11 is lower alkyl; Z.sub.1 is cis or trans --CH.dbd.CH-- or --CH.sub.2 CH.sub.2 --; Z.sub.2 is trans --CH.dbd.CH-- or --CH.sub.2 CH.sub.2 --; X is a single bond or a double bond and X is a single bond when R.sub.4 and R.sub.5 are hydrogen; Y is a single bond or a double bond; n is 1 to 5, m is 0 to 4; and the non-toxic salts. The prostaglandin ethers possess valuable pharmacological properties as modifiers of smooth muscle activity, gastric secretion, blood pressure, lipolysis and the reproductive system. The compounds also induce labor and menses and they can be used for the relief of asthma and nasal congestion. The compounds are also useful as platelet anti-clumping agents and for the inhibition of peptic ulcers.

Alkyl diethers of prostaglandins

Growing community of inventors

Seattle, WA, United States of America

Niels H Andersen